资讯

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population ...

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK ...